Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04857866 | Safety, Tolerability and PK of a Single Subcutaneous Injection of XmAb27564 in Healthy Volunteers | PHASE1 | COMPLETED | 48 | — | — | Apr 19, 2021 | Nov 10, 2022 | Mar 1, 2023 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| Single Ascending Dose - XmAb27564 Subcutaneous injection of Dose A, B, C, D, E or F | EXPERIMENTAL | - |
| Single Ascending Dose - Placebo Subcutaneous injection of placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| XmAb27564 | DRUG | Single ascending dose of XmAb27564 |
| Placebo | DRUG | Single dose of placebo |
Inclusion Criteria: * Total body weight 50.0 to 100.0 kg and body mass index (BMI) 19.0 to 35.0 kg/m2 * In good general health with no clinically significant abnormality identified on medical or laboratory evaluation and no history of any clinically significant disorder, condition, or disease. * A ...